Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 6/20 | 0.37 |
| ▸ | DRD4 | P21917 | 4/20 | 0.37 |
| ▸ | DRD3 | P35462 | 4/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478297 | 0.80 | ALDH1A1 (0.36) | MEN1KMT2AGRM2ALDH1A1 | |
| SCHEMBL4326762 | 0.77 | SMN1; SMN2 (0.43) | MEN1KMT2AHTR1AADRA1BKDM4E | |
| SCHEMBL4332408 | 0.76 | CCR3 (0.56) | KCNH2KDM4EALDH1A1 | |
| SCHEMBL4325925 | 0.76 | MEN1 (0.48) | MEN1KMT2AGRM2DRD2DRD4 | |
| SCHEMBL4331832 | 0.76 | LMNA (0.50) | MEN1KMT2AGRM2DRD2DRD4 | |
| SCHEMBL4318131 | 0.76 | DRD2 (0.47) | MEN1KMT2AGRM2DRD2DRD4 | |
| SCHEMBL4326764 | 0.75 | SMN1; SMN2 (0.42) | MEN1KMT2ADRD2DRD3KCNH2 | |
| SCHEMBL8258107 | 0.75 | MEN1 (0.41) | MEN1KMT2AHTR1AADRA1BKCNH2 | |
| SCHEMBL4320070 | 0.75 | ALDH1A1 (0.56) | DRD2DRD4SIGMAR1HTR7KDM4E | |
| SCHEMBL13913957 | 0.74 | GRM2 (0.43) | MEN1KMT2AGRM2DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069340-A1 | Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders | GRIN1, GRM1, GRIN3A | MEN1 3300/4885KMT2A 2407/4885GRM2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.